Generic drug
Mitoxantrone price, strengths & recalls
Mitoxantrone has no weekly pharmacy acquisition cost. 3 manufacturers make it. It has 3 recalls on record, none ongoing. Its official label last changed on July 17, 2025.
GenericMitoxantrone price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 2 mg/mL injection | Not priced this week | |||
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Mitoxantrone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
MitoXANTRONE Injection, USP (concentrate)
WARNING
Mitoxantrone Injection, USP (concentrate) should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents.
Mitoxantrone Injection, USP (concentrate) should be given slowly into a freely flowing intravenous infusion. It must never be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. (See ADVERSE REACTIONS, General, Cutaneous and DOSAGE AND ADMINISTRATION, Preparation and Administration Precautions).
NOT FOR INTRATHECAL USE. Severe injury with permanent sequelae can result from intrathecal administration. (See WARNINGS, General)
Except for the treatment of acute nonlymphocytic leukemia, mitoxantrone therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving mitoxantrone.
Cardiotoxicity:
Congestive heart failure (CHF), potentially fatal, may occur either during therapy with mitoxantrone or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative mitoxantrone dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In cancer patients, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m2. To mitigate the cardiotoxicity risk with mitoxantrone, prescribers should consider the following:
All Patients:
•
All patients should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to start of mitoxantrone therapy.
•
All patients should have baseline quantitative evaluation of left ventricular ejection fraction (LVEF) using appropriate methodology (ex. Echocardiogram, multi-gated radionuclide angiography (MUGA), MRI, etc.).
Multiple Sclerosis Patients:
•
MS patients with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone.
•
MS patients should be assessed for cardiac signs and symptoms by history, physical examination and ECG prior to each dose.
•
MS patients should undergo quantitative reevaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF. Additional doses of mitoxantrone should not be administered to multiple sclerosis patients who have experienced either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy.
•
MS patients should not receive a cumulative mitoxantrone dose greater than 140 mg/m2.
•
MS patients should undergo yearly quantitative LVEF evaluation after stopping mitoxantrone to monitor for late occurring cardiotoxicity.
For additional information, see WARNINGS and DOSAGE AND ADMINISTRATION.
Secondary Leukemia:
Mitoxantrone therapy in patients with MS and in patients with cancer increases the risk of developing secondary acute myeloid leukemia.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 3 approved generic applications on the market
Mitoxantrone questions
Is mitoxantrone in shortage?
No shortage is reported for mitoxantrone right now. We check the national shortage list every day.
Has mitoxantrone been recalled?
3 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the mitoxantrone label last change?
The official label was last updated on July 17, 2025 (version 25). See what changed.
Talk about mitoxantrone
No comments yet. Questions, tips, what worked for you - start the conversation.